Taylor JT, Ellison S, Pandele A, Wood S, Nathan E, Forte G, Parker H, Zindy E, Elvin M, Dickson A, Williams KJ, Karabatsou K, McCabe M, McBain C, Bigger BW. Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma. Neuro Oncol. 2020 Sep 29;22(9):1289-1301. doi: 10.1093/neuonc/noaa051. PMID: 32227096; PMCID: PMC7523458.

Green D, Eyre H, Singh A, Taylor JT, Chu J, Jeys L, Sumathi V, Coonar A, Rassl D, Babur M, Forster D, Alzabin S, Ponthan F, McMahon A, Bigger B, Reekie T, Kassiou M, Williams K, Dalmay T, Fraser WD, Finegan KG. Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. Oncogene. 2020 Aug;39(33):5553-5569. doi: 10.1038/s41388-020-1379-0. Epub 2020 Jul 13. PMID: 32655131; PMCID: PMC7426263.

Yu KK*, Taylor JT*, Pathmanaban ON, Youshani AS, Beyit D, Dutko-Gwozdz J, Benson R, Griffiths G, Peers I, Cueppens P, Telfer BA, Williams KJ, McBain C, Kamaly-Asl ID, Bigger BW. High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma. PLoS One. 2018 Mar 2;13(3):e0193694. doi: 10.1371/journal.pone.0193694. PMID: 29499065; PMCID: PMC5834163.